Placebo responses in patients with gastrointestinal disorders
- PMID: 17659688
- PMCID: PMC4146777
- DOI: 10.3748/wjg.v13.i25.3425
Placebo responses in patients with gastrointestinal disorders
Abstract
Over the last several years there has been a growing interest in placebo, not only as an inert control in clinical trials, but also in the placebo effect as a group effect as well as a reaction in individual subjects. Methodological factors such as regression to the mean and natural history of the disease play a role in the evaluation of a possible placebo effect. In this report, we discuss several factors including Pavlovian conditioning, beliefs outcome, expectations, and other factors as potential mediators of the placebo response. Placebo effects are common in gastrointestinal diseases and there seems to be no clear difference between placebo effects in functional gastrointestinal diseases (functional dyspepsia and irritable bowel syndrome) and organic gastrointestinal disease (duodenal ulcer and inflammatory bowel disease).
Figures
Similar articles
-
The placebo response in functional bowel disorders: perspectives and putative mechanisms.Neurogastroenterol Motil. 2005 Jun;17(3):325-31. doi: 10.1111/j.1365-2982.2005.00676.x. Neurogastroenterol Motil. 2005. PMID: 15916619 Review.
-
Placebo responses and placebo effects in functional bowel disorders.Eur J Gastroenterol Hepatol. 2012 Jan;24(1):1-8. doi: 10.1097/MEG.0b013e32834bb951. Eur J Gastroenterol Hepatol. 2012. PMID: 21915059 Review.
-
Placebo and placebo effect: their impact on the evaluation of drug response in patients.Dig Dis. 1994 Nov-Dec;12(6):368-77. doi: 10.1159/000171471. Dig Dis. 1994. PMID: 7712618 Review.
-
Placebo effects and their determinants in gastrointestinal disorders.Nat Rev Gastroenterol Hepatol. 2015 Aug;12(8):472-85. doi: 10.1038/nrgastro.2015.117. Epub 2015 Jul 21. Nat Rev Gastroenterol Hepatol. 2015. PMID: 26194942 Review.
-
Placebo effects in functional dyspepsia: Causes and implications for clinical trials.Neurogastroenterol Motil. 2023 Feb;35(2):e14527. doi: 10.1111/nmo.14527. Epub 2023 Jan 2. Neurogastroenterol Motil. 2023. PMID: 36592054 Free PMC article. Review.
Cited by
-
Hypnosis and upper digestive function and disease.World J Gastroenterol. 2008 Nov 7;14(41):6276-84. doi: 10.3748/wjg.14.6276. World J Gastroenterol. 2008. PMID: 19009639 Free PMC article. Review.
-
Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis.World J Gastroenterol. 2017 Jan 14;23(2):336-344. doi: 10.3748/wjg.v23.i2.336. World J Gastroenterol. 2017. PMID: 28127207 Free PMC article.
-
Effect of probiotics on symptoms in korean adults with irritable bowel syndrome.Gut Liver. 2009 Jun;3(2):101-7. doi: 10.5009/gnl.2009.3.2.101. Epub 2009 Jun 30. Gut Liver. 2009. PMID: 20431731 Free PMC article.
-
Intra-sphincteric botulinum toxin in the management of functional biliary pain.Endosc Int Open. 2022 Apr 14;10(4):E521-E527. doi: 10.1055/a-1784-0061. eCollection 2022 Apr. Endosc Int Open. 2022. PMID: 35433205 Free PMC article.
-
Biliary sphincterotomy resets pancreaticobiliary pain refractory to intrasphincteric Botox injections in functional biliary pain.Indian J Gastroenterol. 2024 Dec 6. doi: 10.1007/s12664-024-01709-9. Online ahead of print. Indian J Gastroenterol. 2024. PMID: 39641878
References
-
- Hoffman GA, Harrington A, Fields HL. Pain and the placebo: what we have learned. Perspect Biol Med. 2005;48:248–265. - PubMed
-
- Finniss DG, Benedetti F. Mechanisms of the placebo response and their impact on clinical trials and clinical practice. Pain. 2005;114:3–6. - PubMed
-
- Colloca L, Benedetti F. Placebos and painkillers: is mind as real as matter? Nat Rev Neurosci. 2005;6:545–552. - PubMed
-
- Linde K. The specific placebo effect. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006;49:729–735. - PubMed
-
- Klosterhalfen S, Enck P. Psychobiology of the placebo response. Auton Neurosci. 2006;125:94–99. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources